Mary V. Relling, PharmD,
Chair, Pharmaceutical Sciences,
St. Jude’s Childrens Research Hospital,
View the Presentation
Size: 18.5 MB
Note: You may need to download realplayer (free software) to view this program
As genotyping becomes more widespread, and clinicians learn more about their patients’ genetic makeup, more opportunities are arising to treat genetic conditions that were previously misdiagnosed or unrecognized, or to personalize therapies based on an individual’s genetic information. In order to take advantage of these opportunities, clinicians and laboratorians will need guidance to translate genetic laboratory test results into actionable prescribing decisions for specific drugs. Some in the pharmacogenetics community are now working on generating guidelines in an effort to foster the implementation of pharmacogenetics in the clinical setting.
One group that is making headway in guideline development is the Clinical Pharmacogenetics Implementation Consortium (CPIC). Formed in late 2009, CPIC creates guidelines that are peer-reviewed and published in a leading journal. CPIC’s goals are to address some of the barriers to implementing pharmacogenetic tests in clinical practice. During this recorded webcast, CPIC Team Leader, Mary Relling, PharmD, discusses what can be done to facilitate the use of pharmacogenetics in the clinical setting.
After viewing this program, participants will be able to:
- Provide two examples of drug/gene pairs ready to implement in the clinic
- List two possible challenges to implementing clinical pharmacogenetic testing
- Relate the importance of clinical decision support in incorporating clinical pharmacogenetic tests into the medical record.
Mary Relling, PharmD, earned her undergraduate B.S. degree from the University of Arizona College of Pharmacy and her doctoral degree from the University of Utah College of Pharmacy. She completed post-doctoral fellowships with Dr. William Evans at St. Jude and with Dr. Urs Meyer at University of Basel. She joined St. Jude as a faculty member in 1988, and in 2003 was named chair of the Department of Pharmaceutical Sciences. She is also a professor at the University of Tennessee in the Colleges of Medicine and Pharmacy.
Her primary interests are in treatment of childhood leukemia and pharmacogenetics of antileukemic therapy. Dr. Relling is one of the Principal Investigators within NIH’s Pharmacogenomics Research Network and co-founder of CPIC, the Clinical Pharmacogenetics Implementation Consortium. She has published over 270 original scientific manuscripts. She was elected to the Institute of Medicine in 2009